Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.51 |
| ▸ | PLAU | P00749 | 15/20 | 0.49 |
| ▸ | PLAT | P00750 | 3/20 | 0.49 |
| ▸ | PLG | P00747 | 12/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964840 | 1.00 | F10 (0.51) | F10PLAUPLATPLGST14 | |
| SCHEMBL3826791 | 0.76 | PSMB5 (0.59) | F2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL23052182 | 0.76 | KEAP1 (0.50) | F10NR3C1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13964842 | 0.73 | MEN1 (0.55) | F2SMN1; SMN2 | |
| SCHEMBL13964824 | 0.73 | MEN1 (0.55) | F2SMN1; SMN2 | |
| SCHEMBL23045698 | 0.70 | NR3C1 (0.51) | F10PLAUPLATPLGST14 | |
| SCHEMBL14039732 | 0.69 | F10 (0.55) | F10PLAUPLATPLGST14 | |
| SCHEMBL3825925 | 0.69 | PLAU (0.51) | F10PLAUPLATALDH1A1 | |
| SCHEMBL19396623 | 0.69 | RAB9A (0.46) | F10PLAUPLATPLGST14 | |
| SCHEMBL6266784 | 0.69 | F10 (0.82) | F10PLAUPLGST14HPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099747-A1 | RADIOLABELLING VIA FLUORINATION OF AZIRIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008083729-A1 | RADIOLABELLING VIA FLUORINATION OF AZIRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008083729-A1 | RADIOLABELLING VIA FLUORINATION OF AZIRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1944288-A1 | Radiolabelling via fluorination of aziridines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944288-A1 | Radiolabelling via fluorination of aziridines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | TMEM14C, ARFGEF1, NPFFR1 | F10 2064/4885PLAU 4306/4885PLAT 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.